vs
AVANOS MEDICAL, INC.（AVNS）与Envoy Medical, Inc.（COCH）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是Envoy Medical, Inc.的2412.0倍（$180.9M vs $75.0K）。AVANOS MEDICAL, INC.净利率更高（-0.7% vs -8781.3%，领先8780.6%）。Envoy Medical, Inc.同比增速更快（78.6% vs 0.7%）。AVANOS MEDICAL, INC.自由现金流更多（$21.3M vs $-5.9M）。过去两年Envoy Medical, Inc.的营收复合增速更高（12.7% vs 4.4%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
Envoy Medical是一家专注于植入式听力解决方案研发和商业化的医疗科技企业，核心产品为全植入式中耳听力设备，主要服务于使用常规外置助听器效果不佳的感音神经性听力损失患者，市场覆盖北美、欧洲等地区。
AVNS vs COCH — 直观对比
营收规模更大
AVNS
是对方的2412.0倍
$75.0K
营收增速更快
COCH
高出77.8%
0.7%
净利率更高
AVNS
高出8780.6%
-8781.3%
自由现金流更多
AVNS
多$27.2M
$-5.9M
两年增速更快
COCH
近两年复合增速
4.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $75.0K |
| 净利润 | $-1.3M | $-6.6M |
| 毛利率 | 47.5% | -181.3% |
| 营业利润率 | 1.4% | -8513.3% |
| 净利率 | -0.7% | -8781.3% |
| 营收同比 | 0.7% | 78.6% |
| 净利润同比 | 99.7% | -42.6% |
| 每股收益（稀释后） | $-0.02 | $-0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSCOCH
| Q4 25 | $180.9M | $75.0K | ||
| Q3 25 | $177.8M | $42.0K | ||
| Q2 25 | $175.0M | $78.0K | ||
| Q1 25 | $167.5M | $46.0K | ||
| Q4 24 | $179.6M | $42.0K | ||
| Q3 24 | $170.4M | $56.0K | ||
| Q2 24 | $171.7M | $68.0K | ||
| Q1 24 | $166.1M | $59.0K |
净利润AVNSCOCH
| Q4 25 | $-1.3M | $-6.6M | ||
| Q3 25 | $-1.4M | $-6.5M | ||
| Q2 25 | $-76.8M | $-5.7M | ||
| Q1 25 | $6.6M | $-5.0M | ||
| Q4 24 | $-397.3M | $-4.6M | ||
| Q3 24 | $4.3M | $-6.0M | ||
| Q2 24 | $1.8M | $-3.9M | ||
| Q1 24 | $-900.0K | $-6.3M |
毛利率AVNSCOCH
| Q4 25 | 47.5% | -181.3% | ||
| Q3 25 | 48.4% | -383.3% | ||
| Q2 25 | 52.6% | -200.0% | ||
| Q1 25 | 53.6% | -391.3% | ||
| Q4 24 | 54.6% | -273.8% | ||
| Q3 24 | 54.5% | -233.9% | ||
| Q2 24 | 55.7% | -260.3% | ||
| Q1 24 | 57.1% | -159.3% |
营业利润率AVNSCOCH
| Q4 25 | 1.4% | -8513.3% | ||
| Q3 25 | 0.1% | -13590.5% | ||
| Q2 25 | -42.6% | -6500.0% | ||
| Q1 25 | 6.1% | -11102.2% | ||
| Q4 24 | -233.0% | -10828.6% | ||
| Q3 24 | 7.0% | -8878.6% | ||
| Q2 24 | 3.7% | -7135.3% | ||
| Q1 24 | 2.4% | -8278.0% |
净利率AVNSCOCH
| Q4 25 | -0.7% | -8781.3% | ||
| Q3 25 | -0.8% | -15433.3% | ||
| Q2 25 | -43.9% | -7294.9% | ||
| Q1 25 | 3.9% | -10865.2% | ||
| Q4 24 | -221.2% | -10995.2% | ||
| Q3 24 | 2.5% | -10642.9% | ||
| Q2 24 | 1.0% | -5804.4% | ||
| Q1 24 | -0.5% | -10627.1% |
每股收益（稀释后）AVNSCOCH
| Q4 25 | $-0.02 | $-0.27 | ||
| Q3 25 | $-0.03 | $-0.35 | ||
| Q2 25 | $-1.66 | $-0.32 | ||
| Q1 25 | $0.14 | $-0.29 | ||
| Q4 24 | $-8.64 | $-0.40 | ||
| Q3 24 | $0.09 | $-0.39 | ||
| Q2 24 | $0.04 | $-0.29 | ||
| Q1 24 | $-0.02 | $-0.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | — |
| 总债务越低越好 | $90.3M | — |
| 股东权益账面价值 | $778.2M | $-12.2M |
| 总资产 | $1.1B | $8.6M |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSCOCH
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — | ||
| Q1 24 | $75.8M | — |
总债务AVNSCOCH
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
股东权益AVNSCOCH
| Q4 25 | $778.2M | $-12.2M | ||
| Q3 25 | $778.0M | $-7.7M | ||
| Q2 25 | $776.3M | $-29.9M | ||
| Q1 25 | $839.4M | $-24.2M | ||
| Q4 24 | $828.5M | $-18.8M | ||
| Q3 24 | $1.2B | $-18.5M | ||
| Q2 24 | $1.2B | $-12.4M | ||
| Q1 24 | $1.2B | $-7.4M |
总资产AVNSCOCH
| Q4 25 | $1.1B | $8.6M | ||
| Q3 25 | $1.1B | $8.2M | ||
| Q2 25 | $1.0B | $9.9M | ||
| Q1 25 | $1.1B | $10.4M | ||
| Q4 24 | $1.2B | $11.5M | ||
| Q3 24 | $1.7B | $9.4M | ||
| Q2 24 | $1.7B | $6.7M | ||
| Q1 24 | $1.7B | $8.5M |
负债/权益比AVNSCOCH
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $-5.7M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $-5.9M |
| 自由现金流率自由现金流/营收 | 11.8% | -7809.3% |
| 资本支出强度资本支出/营收 | 3.8% | 229.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | — |
8季度趋势，按日历期对齐
经营现金流AVNSCOCH
| Q4 25 | $28.2M | $-5.7M | ||
| Q3 25 | $14.0M | $-4.3M | ||
| Q2 25 | $6.8M | $-4.5M | ||
| Q1 25 | $25.7M | $-3.7M | ||
| Q4 24 | $57.9M | $-5.1M | ||
| Q3 24 | $23.0M | $-2.6M | ||
| Q2 24 | $27.8M | $-4.6M | ||
| Q1 24 | $-8.0M | $-5.6M |
自由现金流AVNSCOCH
| Q4 25 | $21.3M | $-5.9M | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $-4.2M | $-4.5M | ||
| Q1 25 | $19.0M | $-3.7M | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | $-3.8M | ||
| Q2 24 | $21.9M | — | ||
| Q1 24 | $-12.1M | $-5.7M |
自由现金流率AVNSCOCH
| Q4 25 | 11.8% | -7809.3% | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | -2.4% | -5719.2% | ||
| Q1 25 | 11.3% | -8110.9% | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | -6750.0% | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | -7.3% | -9657.6% |
资本支出强度AVNSCOCH
| Q4 25 | 3.8% | 229.3% | ||
| Q3 25 | 3.9% | 0.0% | ||
| Q2 25 | 6.3% | 1.3% | ||
| Q1 25 | 4.0% | 13.0% | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.8% | 2066.1% | ||
| Q2 24 | 3.4% | — | ||
| Q1 24 | 2.5% | 184.7% |
现金转化率AVNSCOCH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
COCH
暂无分部数据
